Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia

Summary

Significant cognitive impairment (executive functions, memory, attention) is common in schizophrenia affecting up to 80% of patients. But pharmacological treatments (typical and atypical antipsychotic) do not have impact on cognitive functioning. For over 20 years, alternative non-pharmacological therapeutics have been developed in schizophrenia. These techniques called cognitive remediation specifically target cognitive deficits. The first cognitive remediation available for patients was designed to stimulate new learning, or relearning, of cognitive tasks, and thus to improve certain deficient domains. These procedures were efficient in improving cognition as measured by neurocognitive tests but their impact on functioning and daily life was weak. In a second time, compensatory remediation has been developed. Compensatory approaches seek to make improvements in the patient's functioning by avoiding areas of impairment and recruiting other intact cognitive domains or by creating a supportive external environment. In recent meta-analysis compensatory remediation has larger effect-size than classical cognitive remediation, with an impact on patients psychosocial functioning. Recently, Dr E. Twamley (University of California) developed and tested a group-based, manualized, compensatory cognitive training intervention.

Compensatory cognitive training (CCT) is a low-tech, brief intervention and is easily transposable in community care. Our team translated this method into French. The investigators planned a cost -utility study between CCT and treatment as usual in schizophrenia patients with less than 10 years of evolution.

Conditions

• Schizophrenia

Interventions

OTHER

Compensatory cognitive training

In addition to the usual care, method of compensatory cognitive remediation

OTHER

Usual

Usual care

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille

  collaborator OTHER

• University Hospital, Clermont-Ferrand

  collaborator OTHER

• Assistance Publique - Hôpitaux de Paris

  collaborator OTHER

• Hôpital Louis Mourier

  collaborator OTHER

• Centre Hospitalier Charles Perrens, Bordeaux

  collaborator OTHER_GOV

• University Hospital, Strasbourg

  collaborator OTHER

• Hospital Center Alpes-Isère

  collaborator OTHER

• Hôpitaux à Bron

  collaborator OTHER

• Fondation FondaMental

  collaborator OTHER

• University Hospital, Montpellier

  lead OTHER

Principal Investigators

• Delphine DC CAPDEVIELLE, MD-PhD · Montpellier University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-05

Primary Completion

2023-03-28

Completion

2023-03-28

Countries

• France

Study Locations